Advertisement

Journal of Biosciences

, Volume 22, Issue 1, pp 77–89 | Cite as

Changing of Val47 to Asp47 or to Lys47 enhances the immunomodulatory activity of the human Interleukin-l peptide 47–55

  • M. Bruhaspathy
  • S. K. Kar
Article

Abstract

The 47–55 domain of the maturehumanInterleukin-was predicted to be exposed by our computational analysis and confirmed to be so by comparing with X-ray crystallographic as well as nuclear magnetic resonance (NMR) spectroscopic data. Four peptides representing fully or part of this domain with sequences 47–55, 41–61, 45–61 and 50–66 were synthesized and tested for their ability to modulate in vivo, the humoral immune response of Balb/c mice to Shigella dysenteriae 116 kDa antigen(s). The smallest immunomodulatory peptide amongst them was found to be the nonapeptide 47–55. To ascertain the structure-function relationships of this 47–55 peptide, various mutant peptides were synthesized and tested for IL-1β 2 like activity in vivo. Change of Val47 to Asp47 or to Lys47 enhanced its immunomodulatory activity significantly while the change of Gly49 to Asp49 or Glu50 to Ile50 or Asp54 to Ile54 had no such effect. The peptides 47–55 and its mutants were first tested for their ability to elicit inflammatory response like PGE2 synthesis by a sensitive radioimmunoassay. The peptides which did not have any inflammatory activity were then tested for their ability to stimulate antigen primed T-cells in vitro in the presence of sub-optimal concentration of the antigen.

Keywords

Interleukin-l peptide 47–55 immunomodulation Shigella dysenteriae 116 kDa antigen exposed domain mutant peptides 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antoni G, Presentini R, Perin F, Tagliabue A, Ghiara P, Censini S, Volpini G, Villa L and Boraschi D 1986 A short synthetic peptide fragment of human Interieukin-1 with immunostimulatory but not inflammatory activity;J. Immunol,137 3201–3204PubMedGoogle Scholar
  2. Atherton E and Sheppard R C 1989Solid Phase Peptide Synthesis: A practical approach (Oxford: IRL Press)Google Scholar
  3. Chou P Y and Fasman G D 1979 Prediction of beta turns;Biophys. J. 26 367–373Google Scholar
  4. Clore G M, Wingfield P T and Gronenborn AM 1991 High-Resolution Three-Dimensional Structure of IL-1 in solution by Three- and Four-Dimensional Nuclear Magnetic Resonance Spectroscopy;Biochemistry 30 2315–2323PubMedCrossRefGoogle Scholar
  5. Dinarello A. A 1991 Interleukin-1 and Interleukin-1 antagonism;Blood 77 1627–1652PubMedGoogle Scholar
  6. Driscoll P C, Gronenborn A M, Wingfield P T and Clore GM 1990 Determination of the secondary structure and molecular topology of Interleukin-1 by use of two and three dimensional heteronuclear15N-1HNMR spectroscopy;Biochemistry 29 4668–4682PubMedCrossRefGoogle Scholar
  7. Engvall E and Perlmann P 1972 Enzyme linked Immunosorbent assay (ELISA), III. Quantitation of specific antibodies by Enzyme labelled antiimmunoglobulin in antigen coated tubes;J. Immunol. 109 129–135PubMedGoogle Scholar
  8. Falkoff R J M, Muraguchi A, Hong J X, Butler J L, Dinarello A. A and Fauci AS 1983 The effects of Interleukin-1 on human B cell activation and proliferation;J. Immunol. 131 801–805PubMedGoogle Scholar
  9. Kaye J, Gillis S, Mizel S B, Shevac E M, Malek T R, Dinarello A. A, Lachman L B and Janeway A. A Jr 1984 Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: Interleukin-1 is required for expression of receptor for Interleukin-2;J. Immunol. 133 1339–1345PubMedGoogle Scholar
  10. Laemmli U K 1970 Cleavage of structural proteins during the assembly of head of bacteriophage T4;Natural (London) 227 680–685CrossRefGoogle Scholar
  11. Lowenthal J W, Cerottini JC and MacDonald HR 1986 Interleukin-1 dependent induction of both Interleukin-2 secretion and Interleukin-2 receptor expression by thymoma cells;J. Immunol. 137 1226–1231PubMedGoogle Scholar
  12. Manivel V and Rao K V S 1991 Interleukin-1 derived synthetic peptide as an added coadjuvant in vaccine formulation;Vaccine 9 395–397PubMedCrossRefGoogle Scholar
  13. Nencioni L, Villa L, Tagliabue A, Antoni G, Presentini R, Perin F, Silvestri S and Boraschi D 1987 In-vivo immunostimulatory activity of the 163-171 peptide of humanIL-1 ∼;J. Immunol. 139 800–804PubMedGoogle Scholar
  14. Pauletti D, Simmonds R, Dressman G R and Kennedy R C 1985 Application of a modified computer algorithm in determining potential antigenic determinants associated with the AIDS virus glycoproteins;Anal. Biochem. 151 540–546PubMedCrossRefGoogle Scholar
  15. Pike B L and NossalG J V 1985 Interleukin-1 can act as a B cell growth and differentiation factor;Proc. Natl. Acad. Sci. USA 82 8153–8157PubMedCrossRefGoogle Scholar
  16. Priestle J P, Schar H P and Grutter M G 1989 Crystallographic refinement of IL-1β at 2A resolution;Proc. Natl. Acad. Sci. USA 86 9667–9671PubMedCrossRefGoogle Scholar
  17. Rao K V S and Nayak A R 1990 Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human Interleukin-1;Proc. Natl. Acad. Sci. USA 87 5519–5522PubMedCrossRefGoogle Scholar
  18. Simon P L, Kumar V, Lillquist J S, Bhatnagar P, Einstein R, Lee J, Porter T, Green D, Sathe G and Young P R 1993 Mapping of neutralizing epitopes and the receptor binding site of human Interleukin-1β;J. Biol. Chem. 268 9771–9779PubMedGoogle Scholar
  19. Staruch M J and Wood D D 1983 The adjuvanticity of Interleukin-1in vivo;J. Immunol. 130 2191–2194PubMedGoogle Scholar

Copyright information

© Indian Academy of Sciences 1997

Authors and Affiliations

  1. 1.Centre for BiotechnologyJawaharlal Nehru UniversityNew DelhiIndia

Personalised recommendations